Depopulated Bovine Ureteric Xenograft for Complex Haemodialysis Vascular Access  by Darby, C.R. et al.
*Correspond
Consultant V
Centre, Chur
UK.
E-mail address
1078–5884/00Depopulated Bovine Ureteric Xenograft for Complex
Haemodialysis Vascular Access
C.R. Darby,1,2* D. Roy,1 D. Deardon1 and A. Cornall11Oxford Transplant Centre, and 2Department of Vascular Surgery, Headington, Oxford, UKObjectives. To assess performance of a decellularised bovine ureter vascular graft for haemodialysis in patients for whom
conventional access was not possible.
Methods. The SynerGraftw Vascular Graft Model 100 (SGVG 100) is a bovine ureter modified by a tissue-engineering
depopulation technology and uniquely it is not chemically cross-linked. SGVG 100 was implanted in patients with a failed
fistula or vascular access grafts. Graft patency was the primary outcome; secondary outcomes included adverse events and
associated treatments.
Results. 25 SGVG 100 were implanted in 23 patients; mean age was 59G14 years. Mean follow-up was 370 days. The
mean time to occlusion (19 events) was 215G141 days with patency re-established in 14 of 18 surgical interventions. Thirty
angioplasties were performed on 14 SGVG 100 for luminal/anastomotic stenosis. Two grafts demonstrated areas of dilation;
however, both grafts continue to be usable at last reported follow-up (930 and 602 days) with no further changes in graft size.
Primary patency, assisted primary patency, secondary patency, and freedom from infection were 29, 45, 81, and 95% at 1
year, respectively.
Conclusions. This report demonstrates SGVG 100 is a stable vascular access conduit, providing a suitable graft alternative
when autologous vein is not available.Keywords: Vascular access; Bovine ureter; Tissue engineering; Surgery; Outcome.Introduction
The incidence of end stage renal failure treated by
dialysis continues to increase in both Europe and the
USA.1 Haemodialysis is the most common modality
for dialysis, comprising 92% of new patients that are
treated in the USA.2 The gold standard for vascular
access is the creation of a primary arteriovenous fistula
(AVF) using native vein. In Europe and more recently
in America the benefits of this approach have been
fully recognised and this approach is formalised by the
DOQI guidelines in the USA.3 However, it is
recognised that there will always be a percentage of
patients for whom use of native vein is not possible.
Hence, there is an extensive history in the use of
synthetic arterio venous grafts (AVG) for this purpose.
The most widely used bridge graft material for
haemodialysis is polytetrafluoroethylene (PTFE).4,5ing author. Mr C.R. Darby, MBBS, FRCS, MD,
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patency rates of between 41 and 68% at 1 year.5
The main complications for PTFE grafts used for
haemodialysis access have been thrombosis, reported
to contribute to 70% of the failures6,7 and infection,
which on average occurs in 10% of implanted PTFE
grafts.5,7–9
In the past before the widespread use of synthetic
grafts, biological grafts were used for vascular access
and peripheral bypass surgery. Cryopreserved vascu-
lar allograft tissue has been shown to be useful in
difficult vascular access situations.10,11 Cryopreserved
vascular tissue is effective in cases of active infection
and can be placed directly in the infected field with a
low recurrence of infection.10–12
Xenografts, including natural bovine tissues
(carotid artery, Artegraftw and visceral veins,
Procolw and ovine collagen tubes) have been used
for haemodialysis access. These grafts are tradition-
ally treated with glutaraldehyde cross-linking to
stabilise the connective tissue matrix. Reported
results from clinical studies have been mixed with
failures related to aneurysm formation, calcification
and infection.13–19Eur J Vasc Endovasc Surg 31, 181–186 (2006)
doi:10.1016/j.ejvs.2005.07.006, available online at http://www.sciencedirect.com onved.
C. R. Darby et al.182The graft described here is unlike any other
previously implanted in that it is decellularised to
remove antigenicity and there is no chemical treatment
allowing neo cellularisation by the host and the
retention of some of the native biomechanical charac-
teristics. To generate this graft a new method to
process xenograft tissue was developed, SynerGraftw
Vascular Graft Model 100 (SGVG 100, CryoLife, Inc.,
Kennesaw, GA, USA). The cellular elements have been
removed using a proprietary SynerGraft antigen
reduction technology. This technology was developed
as an alternative to chemical cross-linking to render
biological grafts non-immunogenic. Preliminary
studies demonstrated removal of cells with retention
of natural biomechanical characteristics (compliance,
longitudinal and circumferential tensile strength).20
There has been no previously published data in
humans using this graft for vascular access. However,
in a dog arteriovenous shunt model, the primary
patency of the SGVG 100 at 6 months was 72.6%
(versus 58.6% for a PTFE conduits) and the 12-month
patency was no different from PTFE (58.6 and 57.4%,
respectively). There were no aneurysms in the SGVG
100 grafts. There were no infections among the SGVG
100 grafts, despite twice weekly sham access, whereas
three of the PTFE implants became infected with
Staphylococcus intermedius (epidermidis). Migration
of interstitial cells into the previously acellular matrixTable 1. Patient demographics
Analysis parameter
Age (mean G standard deviation)
Age range (minimum to maximum)
Gender
Medical history
Diabetes
Hypertension
Peripheral vascular disease
Coronary artery disease
Smoking history (current or previous)
Polycystic kidneys
Chronic pyelonephritis
Previous procedures on limb (meanGstandard deviation)
0
1
2
3C
Years on haemodialysis (meanGstandard deviation)
0–1 year
2–3 years
4–5 years
6C years
Indication for surgery†
Primary access
Failed fistula
Failed graft
Infection
* Twenty-five grafts implanted in 23 patients (patients with two graf
† May have more than one entry per graft.
Eur J Vasc Endovasc Surg Vol 31, 2 2006was ongoing as early as 2.5 months, with additional
re-cellularisation and collagen biosynthetic activity
observed at 1 year.21
These preclinical studies supported the application
of the SGVG 100 conduit for clinical use in humans.
Hence, this single centre non-randomised study was
performed to review the performance of this novel
biological graft.Materials and Methods
The bovine ureter (SGVG 100) is obtained from cows in
the USA. The graft is processed by hypotonic water
lysis and incubation with DNAse and RNAse to
destroy the cellular component, which are removed
by isotonic washing over a 12-day period. The graft is
gamma irradiated to sterilise it. The graft is available
in 25, 35 and 50 cm lengths of approximately 0.7 cm
internal diameter packed in pouches of sterile saline.
The graft can be kept at room temperature with a
2-year shelf life.Patients
Patients were deemed suitable for treatment with a
bovine graft if multiple attempts to fashion vascular
access had been made previously and attempts atSGVG 100 grafts (nZ25)*
59.0G14.3 years
35.0 to 81.0 years
8 male, 17 female
5
13
5
5
11
4
3
2.4G1.0
2
2
6
15
4.2G1.6 years
2
9
7
7
1
21
9
1
ts are treated as independent entries in the analysis).
Bovine Ureter for Vascular Access 183autogenous venous access was not likely to be
successful (Table 1). Access in the lower limb was
created only in patients with an occluded superior
vena cava. No special consent was required as the
product was licensed in the UK for this indication.
However, a detailed patient information leaflet
describing the product and any potential problems
was provided and consent was taken from each
patient for recording of all demographic, surgical
and outcome data.Techniques
All patients received their access graft under a general
anaesthetic. Patients received a single dose of anti-
biotic prophylaxis (cefuroxime). No heparin or ster-
oids was given. The brachial or femoral artery was
prepared and clamped. An end graft to side recipient
native vessel anastomosis was prepared with no
undue handling and no clamping of the graft allowed.
The venous site was prepared and the graft tunnelled
avoiding traction injury. The graft was pulled down a
hollow tunneller to achieve this. The graft was
anastomosed to the vein end to side. Clamps were
removed from the vein and artery and flow restored.Data and statistics
The data was entered prospectively onto an online
database. Outcome data was recorded, determining
operative technique, primary patency, assisted pri-
mary patency and secondary patency, morbidity and
mortality. Endpoints were set according to the
reporting standards for arterio-venous access of the
Society for Vascular Surgery and the American
Association for Vascular Surgery.22 A data entry form
was completed prospectively at the following time
points, preoperatively, at the time of surgery, at each
post operative follow up appointment, at the time of
graft complication, at the time of color duplex
assessment or flow monitoring and at patient death.
Data was analysed by Kaplan–Meier statistical anal-
ysis for the calculation of overall freedom from events.Results
The range of follow-up time was 44–930 days, with a
mean follow-up time of 370G256 days and total
follow-up time of 9247 days (25.3 patient-years).
Follow-up data collection was 100% complete. Of the
25 SGVG 100 implanted, 22 went on to undergo
dialysis access (one occluded day 44 and two arecurrently awaiting first dialysis—day 46 and day 48).
The range of time to first access was 21–148 days
(mean 67 days, median 55 days). Intended first
needling was at 30 days but early needling occurred
for total lack of alternative access. No problems were
encountered in these early-needled grafts. The pri-
mary reason for delayed access in nine patients
(O60 days) was limb oedema, graft needling not
required or central stenosis requiring prior treatment.
In this series, varying degrees of oedema or limb
swelling was reported in seven grafts (two with
known central vein stenosis) all seven patients with
early oedema went on to undergo haemodialysis.
In these two patients fusiform dilatation (!50%
increase in diameter) was seen only at needling sites
and no graft was lost or revised for aneurysmal
dilatation. Both grafts continue to be needled at last
reported follow-up with no further changes in graft
size (930 and 602 days). Distal revision with a second
piece of SGVG 100 was performed in five grafts. One
graft developed an anastomotic pseudoaneurysm at
the arterial anastomosis and underwent an uneventful
localised surgical repair. A summary of all reported
complications is listed in Table 2. There were four
mortalities reported in the series due to gastrointesti-
nal bleeding at 369 days, chronic renal failure at
486 days, anoxic brain damage at 544 days and sepsis
at 601 days. The deaths were not related to the SGVG
100, and all grafts were reported as patent at the time
of death.
Two SGVG 100 grafts in the series developed
complications related to infection. In the first, a patient
developed an infection on day 587, which was initially
treated with antibiotics. The graft underwent revision
on day 604 to replace the infected needling site with a
second SGVG 100. The old section continued to be
needled and the graft remains patent at last follow-up.
The second infection in a graft placed in the upper
thigh, developed on day 122 and underwent a revision
with a short replacement section of new SGVG 100.
The surgery was initially successful, but the graft
thrombosed 4 days postoperative after insertion of a
tunnelled line in the ipsi-lateral common femoral vein
and could not be saved via thrombectomy.
A total of 19 occlusions were reported in 12 SGVG
100 grafts (Table 2). The mean time to occlusion was
215G141 days (range 34–604 days). Surgery to re-
establish patency was successful in 14 of 18 attempts.
One patient refused exploration after the SGVG 100
graft clotted due to a hypotensive episode.
As shown in Table 3, in 19 of the 25 cases a total of 49
procedures have been required in an attempt to
maintain or re-establish patency. Hence, the interven-
tion rate to maintain or re-establish patency was 1.94Eur J Vasc Endovasc Surg Vol 31, 2 2006
Table 2. Reported graft complications
Events* SGVG 100 grafts # of grafts w/event Linearised rate (events/year)
Occlusion 19 12 0.75
Stenosis 32† 14 1.26
Dilatation 2 2 0.08
Infection 2 2 0.08
Haematoma 2 2 0.08
Pseudoaneurysm 1 1 0.04
Bleeding complication 1 1 0.04
Steal 0 0 0.00
Rupture 0 0 0.00
Oedema/swelling 7‡ 7 0.28
* More than one complication may be reported for a single graft at follow-up.
† Six in the native vein.
‡ Two with known central vein stenosis.
C. R. Darby et al.184per graft year. Thirty interventional radiology pro-
cedures in 14 SGVG 100 grafts were performed to treat
luminal stenosis (Table 3). Angioplasty was the
primary treatment technique (nZ30) with patency
re-established in all 30 procedures (four of 14 grafts
accounted for 17 procedures).
Primary patency, assisted primary patency, second-
ary patency, and freedom from infection were 29, 49,
81, and 95% at 1 year, respectively (Table 4, Fig. 1). The
event rates are shown in Table 5, demonstrating the
incidence of thrombosis to be 0.75 events per graft year
with an average of 0.76 occlusions per graft.Discussion
All those responsible for vascular access surgery will
recognise a patient group in which conventional
vascular access has failed or is not possible. Previous
biological grafts have been used for this type of patient
group. These older xenografts were chemically fixed to
destroy xeno-antigenicity. However, this makes them
less biocompatible. There is also a tendency to
aneurysm formation, late aldehyde initiated calcifica-
tion and thrombosis.23,24 Graft handling and suturing
of the SGVG 100 was found to be straightforward. It is
advisable to avoid clamping the graft, excessive
traction or handling of the collagen scaffold until it
repopulates. With the graft studied there were no earlyTable 3. Reported treatment procedures
Treatment type* SGVG 100 grafts (nZ19)
Angioplasty 30
Thrombolysis 0
Thrombectomy 12†
Graft explant or ligated 1
Graft revision‡ 6
* More than one treatment may be reported for a single graft at
follow-up.
† Concomitant angioplasty and stent placement in a single graft.
‡ Five grafts with a second piece of bovine graft inserted.
Eur J Vasc Endovasc Surg Vol 31, 2 2006thromboses or infections (30 day) showing that the
graft is easily inserted resistant to kinking and clotting
and the patient does not require anticoagulation.
Needling for dialysis was delayed to 30 days after
insertion. This was based on the assumption that the
graft will become stronger with time as host cells
incorporate into a collagen matrix.25,26 There is
evidence from dog work21 and from grafts in this
series (data not shown) that capillaries, myocytes,
fibroblasts, neo collagen and endothelium do indeed
appear.27 In several patients needling was performed
early (14 days) after alternative access was lost. This
did not prove to be a problem and it is possible that the
graft could be needled earlier but we have no
experience of this.
The study group included patients with absence of
native vein, failed prior grafts, active infection, obesity
and central vein stenosis. The patient demographics,
time on dialysis and prior surgical attempts at access
reflect this unfavourable patient study group (Table 1).
As a consequence it is difficult to compare the results
from this series with published data using for exampleFig. 1. Actuarial primary and secondary patency curves at 1
year. Patency (%)Gstandard error (%); solid line (primary);
dashed line (secondary).
Table 4. Actuarial outcome table of performance variables at 1 year
Performance
variable
# of events % Event free Standard error (%) Lower 95% CI (%) Upper 95% CI (%)
Primary patency 18 29 10 9 49
Primary assisted
patency
12 45 11 23 67
Secondary patency 6 81 9 63 99
Mortality 4 100 0 100 100
Infection 2 95 5 88 100
Confidence limits (95%) were calculated as 1.96!SEGevent (%).
Bovine Ureter for Vascular Access 185PTFE. Furthermore, we know that the threshold for the
use of PTFE is much lower in the USA where most of
the large studies of PTFE have been performed.28 In a
large survey of PTFE in the USA, primary patency rate
was 38% at 1 year and 25% at 2 years.29 PTFE was
found to have a 72% secondary patency at 12 months
when 70% of PTFE grafts were the first graft procedure
performed.29 By comparison secondary patency for
SGVG in this series was 81%, with only 4% (one of 25)
of grafts places as the first access procedure. This
secondary patency meets the National Kidney Foun-
dation-Dialysis Outcomes Initiative goal of 70% at 12
months.4
One year primary patency without intervention
was 29% but improved to 45% when considering
grafts that were treated by angioplasty or revision
without thrombosis. It had been hoped that the
improved biomechanical properties of the graft
might ameliorate the venous outflow stenosis seen
with synthetic grafts. However, this has not been the
case in these high-risk patients. Stenoses tended to
occur in the distal end of the graft and not in the native
vein unlike with PTFE and this made it easier to
salvage. Stenoses when resected were proliferative in
nature on histology (data not shown) and those treated
radiologically responded readily to angioplasty.30 As a
result we now assess the grafts regularly by thermo-
dilution flow monitor initially every 3 months and
perform duplex ultrasound on any graft showing
decreasing flow characteristics or rising venous
pressures. It would appear for the SGVG graft asTable 5. Linearised event rates
Event Number of events Linearised rate
(events/year)
Infection 2 0.08
Thrombosis 19 0.75
Total Interventions 49 1.94
Abandonment
(infection)*
1 0.04
Abandonment
(thrombosis)
4 0.16
Abandonment (all) 6 0.24
* InfectionCocclusion in a single graft.with PTFE,31 that a high level of monitoring and
intervention will still be required.
Infection rates have been low and it would appear
that the rate is lower than historical reports on PTFE
(circa 10%).5,7–9 This may well be the greatest asset for
the graft. It could be postulated that the graft would
have the ability to resist and remove infection. This
would be supported by the low infection rates in the
dog,21 in this study and when cryopreserved non
cross-linked tissue was placed directly in the infected
field.10–12
In conclusion, the SGVG 100w graft may be
advantageous to other biological grafts as it has wall
compliance properties that may limit myo intimal
hyperplasia, has a substantial wall thickness to avoid
dilatation, ability to repair wall damage from needling,
and ability to remove infection form needle tracts.27
Our initial experience of the SGVG 100w shows that it
was a safe and promising tool in these difficult
patients. Results should improve further as less
challenging patients are studied. There would now
be a strong case for comparison with PTFE in a
randomised trial but perhaps still concentrating on
tertiary vascular access patients.Acknowledgements
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